Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia

• Autoři: MAYER Jiří; ČIČÁTKOVÁ Petra; KOVACOVA Lenka; JAROŠOVÁ Marie; KARAS Michal; JINDRA Pavel; KLAMOVA Hana; MACHOVA POLAKOVA Katerina; CERNA Olga; CMUNT Eduard; BELOHLAVKOVA Petra; ZAK Pavel; FABER Edgar; PAPAJIK Tomas; STEJSKAL Lukas; JEŽÍŠKOVÁ Ivana; WEINBERGEROVÁ Barbora; JURČEK Tomáš; HORŇÁK Tomáš; ŽÁČKOVÁ Daniela; RANSDORFOVA Sarka; HOLZEROVA Milena; PAVLÍK Tomáš
• Rok publikování: 2025
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: American Journal of Hematology
• Fakulta / Pracoviště MU: Lékařská fakulta
• www: https://onlinelibrary.wiley.com/doi/10.1002/ajh.27608
• Doi: https://doi.org/10.1002/ajh.27608
• Klíčová slova: additional chromosomal abnormalities; chronic myeloid leukemia; cytogenetics; prognosis

Přiložené soubory

• Clinical_and_Prognostic_Significance_of_Additional_Chromosomal_Abnormalities_at_Diagnosis_of_Chronic_Myeloid_Leukemia.pdf

• Popis: Today, the prognosis for CML patients is excellent, but some stilldo not respond well to therapy, progress, or die from the disease(suppl. refs. 1–4). Even in the era of tyrosine kinase inhibitors(TKIs), prognostic markers that can identify high-risk patientsare still needed. Shortly after the discovery of translocation be-tween chromosomes 9 and 22, the hallmark of CML, it becameapparent that this was not the only chromosomal abnormal-ity. In 1976, Mitelman et al. described additional nonrandomchromosomal abnormalities (ACAs) in blast phase CML, andthe three most common aberrations were named “major route”(suppl. ref. 5).

Související projekty

• Národní ústav pro výzkum rakoviny